May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Pars Plana Vitrectomy with Intravitreal Triamcinolone for Diabetic Macular Oedema
Author Affiliations & Notes
  • Z.K. Ockrim
    Medical retina,
    Moorfields Eye Hospital, London, United Kingdom
  • P. Hykin
    Medical retina,
    Moorfields Eye Hospital, London, United Kingdom
  • E. Ezra
    Vitreoretinal,
    Moorfields Eye Hospital, London, United Kingdom
  • Z. Gregor
    Vitreoretinal,
    Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  Z.K. Ockrim, None; P. Hykin, None; E. Ezra, None; Z. Gregor, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4131. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z.K. Ockrim, P. Hykin, E. Ezra, Z. Gregor; Pars Plana Vitrectomy with Intravitreal Triamcinolone for Diabetic Macular Oedema . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4131.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:The aim of this study was determine whether pars plana vitrectomy and intravitreal triamcinolone in patients with diabetic maculopathy reduces macular thickness and volume as measured by optical coherence tomography (OCT) and improves visual acuity. Methods:A prospective pilot study of 7 patients undergoing pars plana vitrectomy with intraocular triamcinolone for diabetic macular oedema. Inclusion criteria were patients with persistent clinically significant macular oedema following at least one prior macular laser treatment. Best corrected visual acuity (BCVA) in the study eye was between 19 and 59 letters (Snellen equivalent of 3/60 and 6/18). Moderate – severe macular ischaemia and co–existing ocular disease were exclusion criteria. Patients had baseline examinations of BCVA, OCT, macular stereo photographs and fundus fluorescein angiography. Pars plana vitrectomy with intravitreal triamcinolone (4mg) performed and all patients were re–examined at 1 week, 1 month, 4months. Results: At one month the central macular thickness had dramatically reduced, decreasing from a preoperative median of 418 (285 – 590) to 195 (160–276). Visual acuity improved by at least 1 line of on the ETDRS chart. Conclusions: In this pilot study combined pars plana vitrectomy with intravitreal triamcinolone substantially reduces diabetic macular oedema.

Keywords: diabetes • vitreoretinal surgery • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×